ARVO to award young scientists

Article

A series of awards granted to scientists under the age of 45 has been announced by the Association for Research in Vision and Ophthalmology (ARVO) Foundation for Eye Research (AFER) and Merck & Co, Inc.

A series of awards granted to scientists under the age of 45 has been announced by the Association for Research in Vision and Ophthalmology (ARVO) Foundation for Eye Research (AFER) and Merck & Co, Inc.

The ARVO-AFER/Merck Innovative Ophthalmology Research Award (IORA) grants, totalling $70,000 per cycle, will be awarded biennially to young scientists of MD, PhD or equivalent level throughout the world who have made "innovative contributions to ophthalmology research". The awards are granted in the categories of glaucoma and back-of-eye diseases, and first and second place prizes will be awarded in each category. In addition to grant funding, award recipients will receive travel expenses and registration fees for the annual ARVO meeting.

The award, formerly run by Merck as the Chibret Award, has been granted to more than 50 scientists since its initiation in 1982. Submissions for the first ARVO-AFER/Merck IORA have now closed, and the winners will be announced at the ARVO 2009 annual meeting, to be held on May 3–7 in Fort Lauderdale, US. The application process for the 2011 award will begin in 2010.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.